The FDA approved AbbVie's Vyalev for advanced Parkinson's disease, providing a 24-hour subcutaneous infusion of levodopa therapy. The treatment showed superior results in improving motor fluctuations compared to oral medication. Medicare coverage is expected in late 2025.